Testosterone Enanthate Global Regulatory Status

FDA Approval History and Current Indications

Testosterone enanthate received its original FDA approval in 1953 under the brand name Delatestryl, making it one of the oldest continuously marketed injectable androgens in the United States [1]. The New Drug Application (NDA) was held by Endo Pharmaceuticals, though the product has since been joined by multiple Abbreviated New Drug Application (ANDA) generics listed in the FDA Orange Book [2].

The approved indication is narrow by modern standards. The label restricts use to replacement therapy in males with confirmed testosterone deficiency caused by primary hypogonadism (testicular failure) or hypogonadotropic hypogonadism (pituitary-hypothalamic insufficiency) [2]. FDA specifically cautions that testosterone products are not approved for age-related declines in testosterone, a distinction that shapes prescribing patterns across the country. The agency reinforced this position in a 2015 Safety Communication, stating that the benefits and safety of testosterone for so-called "low-T" without a structural or genetic etiology had not been established [3].

Labeling carries a class-wide warning about potential cardiovascular risk, abuse potential, and polycythemia. The recommended intramuscular dose is 50 to 400 mg every 2 to 4 weeks, titrated to serum testosterone levels [2]. Prescribers must also comply with Schedule III controlled-substance documentation requirements under the Controlled Substances Act.

The 2015 FDA Class-Wide Labeling Changes

March 2015 marked a turning point. The FDA issued a required labeling revision for every testosterone product on the US market, including enanthate, cypionate, undecanoate, gels, and patches [3]. Two changes stood out.

First, the agency narrowed the indicated population. Labels were updated to specify that testosterone replacement is approved only for men with low testosterone caused by certain medical conditions (disorders of the testes, pituitary gland, or brain), confirmed by laboratory testing. The language explicitly excluded age-related testosterone decline as an approved indication [3].

Second, a new warning about possible increased cardiovascular risk was added. This decision followed two observational studies that reported higher rates of myocardial infarction and stroke among testosterone users. One retrospective cohort study of 55,593 men published in PLOS ONE found a two-fold increase in MI rates in the 90 days after filling a testosterone prescription among men aged 65 and older [4]. A separate VA database study of 8,709 men with pre-existing coronary disease reported a 29% absolute increase in the composite of death, MI, and stroke at 3 years [5].

The FDA acknowledged that data were conflicting and required ongoing evaluation. That evaluation led directly to the TRAVERSE trial mandate.

The TRAVERSE Trial and Cardiovascular Safety

FDA required a post-marketing cardiovascular outcomes trial as a condition of continued approval for testosterone undecanoate (Jatenzo, Tlando), and the results from TRAVERSE (Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men) reshaped the regulatory conversation for all testosterone formulations [6].

TRAVERSE enrolled 5,246 men aged 45 to 80 with hypogonadism and pre-existing cardiovascular disease or elevated cardiovascular risk. At a mean follow-up of 33 months, the primary endpoint of first MACE (cardiovascular death, non-fatal MI, or non-fatal stroke) occurred in 7.0% of the testosterone group versus 7.3% of the placebo group (hazard ratio 0.96 to 95% CI 0.78 to 1.17), meeting the pre-specified non-inferiority margin [6]. The trial provided the first randomized evidence that testosterone replacement did not increase MACE in a high-risk population. Dr. Shalender Bhasin, lead investigator, stated: "These findings should provide reassurance that testosterone replacement therapy, when prescribed for men who have hypogonadism, does not increase the short-to-intermediate-term risk of major cardiovascular events" [6].

One safety signal did emerge. Pulmonary embolism occurred more frequently in the testosterone arm (0.9% vs. 0.5%), and atrial fibrillation rates were numerically higher [6]. The FDA has not yet issued a formal label update in response to TRAVERSE, though an advisory committee review is anticipated.

EMA and European Regulatory Framework

In Europe, testosterone enanthate is authorized at the national level across EU member states. No centralized European Medicines Agency (EMA) Marketing Authorization exists for enanthate specifically, though the EMA conducted a class-wide review of all testosterone-containing medicines in 2014 under Article 31 of Directive 2001/83/EC [7].

The Pharmacovigilance Risk Assessment Committee (PRAC) concluded in October 2014 that the evidence did not support an increased risk of cardiac events with testosterone replacement. The review was triggered by a signal detected through EudraVigilance and the same observational studies that later prompted the FDA action [7]. PRAC recommended updated product information to include warnings about venous thromboembolism (VTE), aligning with accumulating case reports of deep vein thrombosis and pulmonary embolism in testosterone users.

Individual member states regulate testosterone enanthate as a prescription-only medicine. Germany, where the product has been marketed as Testoviron Depot by Bayer since the 1950s, maintains one of the largest user populations in Europe. The product requires a standard prescription (Kassenrezept) and is not classified under the Betäubungsmittelgesetz (narcotics law), unlike in the US where all testosterone products carry Schedule III status [8].

In the United Kingdom, testosterone enanthate is available as a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is classified as a Class C controlled substance under the Misuse of Drugs Act 1971, permitting personal possession but prohibiting supply without authorization [8].

Australia and Canada

Australia's Therapeutic Goods Administration (TGA) lists testosterone enanthate on the Australian Register of Therapeutic Goods (ARTG) as a Schedule 4 (Prescription Only) medicine. The product is PBS-listed (Pharmaceutical Benefits Scheme) for confirmed male hypogonadism with two morning testosterone levels below the laboratory reference range, ensuring subsidized access for qualifying patients [9]. The TGA follows a post-market review model similar to the FDA's, requiring sponsors to submit Periodic Safety Update Reports (PSURs).

Health Canada approves testosterone enanthate under a Drug Identification Number (DIN) for androgen replacement therapy in confirmed deficiency states. Canadian labeling mirrors the FDA's cardiovascular warnings. The product is listed as a controlled substance under Schedule IV of the Controlled Drugs and Substances Act, a less restrictive classification than the US Schedule III designation [10].

WHO Essential Medicines List

The World Health Organization has included testosterone (as the enanthate ester) on the Model List of Essential Medicines since 1977, listed under Section 18.5 (Androgens) [11]. This designation signals that testosterone replacement is considered a basic healthcare need for populations with confirmed androgen deficiency. Over 150 countries reference the WHO Model List when constructing national formularies, which has facilitated global availability of injectable testosterone enanthate even in resource-limited settings.

The T-Trials: Regulatory-Grade Efficacy Evidence

While not a regulatory trial in the traditional phase-III sense, the Testosterone Trials (TTrials) funded by the National Institute on Aging provided seven coordinated randomized, placebo-controlled studies in 788 men aged 65 and older with serum testosterone below 275 ng/dL [12]. Results published in The New England Journal of Medicine in 2016 showed that 12 months of testosterone gel (raising median testosterone from 232 to 565 ng/dL) improved sexual function, walking distance, and mood compared with placebo.

These findings gave regulators a clearer picture of the benefit side of the benefit-risk equation. The sexual function trial showed a mean increase of 0.58 points on the PDQ-Q4 (Psychosexual Daily Questionnaire desire domain) versus 0.10 for placebo (P<0.001). The physical function trial showed a mean increase of 6.0 meters on the 6-minute walk test (P = 0.04) [12]. The data did not resolve the cardiovascular question, which required the larger TRAVERSE trial discussed above.

Post-Market Surveillance Mechanisms

Regulatory agencies rely on multiple systems to monitor testosterone safety after approval. The FDA Adverse Event Reporting System (FAERS) collects voluntary and mandatory reports from manufacturers, healthcare professionals, and consumers. A 2019 FAERS analysis found that testosterone products were associated with 15,428 adverse event reports between 2004 and 2018, with the most common signals being polycythemia (erythrocytosis), cardiovascular events, and mood disturbance [13].

The FDA Sentinel System provides active surveillance using electronic health records and claims data from over 100 million patients. A Sentinel analysis published in 2019 examined 544,115 testosterone-exposed men and found no statistically significant increase in MI or stroke compared with matched unexposed controls (adjusted HR 1.02 to 95% CI 0.92 to 1.12 for MI; adjusted HR 0.97 to 95% CI 0.86 to 1.10 for stroke) [14].

In Europe, EudraVigilance serves an equivalent function. The system flagged a disproportionate number of VTE reports for testosterone products, which contributed to the 2014 PRAC review and subsequent labeling updates [7].

Controlled-Substance Scheduling: A Jurisdiction-by-Jurisdiction Comparison

Testosterone enanthate's scheduling varies significantly across regulatory jurisdictions. This has direct implications for prescribing burden, patient access, and pharmacy dispensing rules.

In the United States, the 1990 Anabolic Steroids Control Act placed all anabolic-androgenic steroids, including testosterone enanthate, under Schedule III of the Controlled Substances Act [15]. Prescriptions require a DEA-registered prescriber, and refills are limited to five within six months. Telemedicine prescribing of Schedule III substances became permanently permissible under the 2024 DEA rulemaking, which removed the in-person examination requirement for established patient-prescriber relationships [15].

Australia classifies testosterone as Schedule 4 (no controlled-substance overlay), simplifying prescribing relative to the US. Canada's Schedule IV classification similarly imposes fewer administrative requirements. The UK's Class C designation sits between these approaches. Personal possession is legal, but distribution carries penalties of up to 14 years' imprisonment [8].

Germany and most EU member states do not classify testosterone as a controlled substance for medical use, though anti-doping laws prohibit non-medical possession and distribution. France requires a specialized prescription (ordonnance sécurisée) for testosterone products, adding an administrative layer absent in neighboring countries.

Current Labeling Warnings Across Agencies

All major regulatory agencies now require warnings covering similar safety domains, though the specific language differs.

The FDA label includes warnings for: secondary exposure risk (particularly in children and women), polycythemia (hematocrit monitoring required), sleep apnea exacerbation, hepatic effects with oral formulations, venous thromboembolism, and cardiovascular risk. A Medication Guide must accompany each dispensed prescription [2].

The EMA-aligned SmPC (Summary of Product Characteristics) includes warnings for: hepatic tumors (rare), polycythemia, prostatic effects, edema in patients with cardiac or renal insufficiency, and skeletal maturation acceleration in adolescents [7]. The cardiovascular warning is less prominent than the FDA version, reflecting PRAC's conclusion that existing evidence did not confirm increased cardiac risk.

The TGA Product Information aligns closely with the EMA SmPC but adds specific guidance on monitoring hematocrit at 3, 6, and 12 months after initiation, with a recommended threshold of 54% for dose reduction or temporary discontinuation [9].

Across all jurisdictions, testosterone enanthate remains contraindicated in breast carcinoma in males, known or suspected prostate carcinoma, and pregnancy [2][7][9].